Biohaven receives fda may proceed letter to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after covid-19 infection

Biohaven receives fda may proceed letter to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after covid-19 infection.biohaven pharmaceutical holding company ltd - phase 2 study to start within weeks, in collaboration with thomas jefferson university.biohaven pharmaceutical holding company ltd - biohaven plans to study intranasal vazegepant.biohaven pharmaceutical holding - clinical trial will assess potential benefits of cgrp receptor-blockade in mitigating an excessive immune response.
BHVN Ratings Summary
BHVN Quant Ranking